Imatinib Completed Phase 2 Trials for Chronic Myelogenous Leukemia (CML) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01003054Autologous Transplantation for Chronic Myelogenous Leukemia